FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

632 letters match. Newest first.

  1. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  2. Chengdu Innovation Pharmaceutical Co., Ltd.

    FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.

    High risk
  3. Wuhu Nuowei Chemistry Co., Ltd.

    FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.

    High risk
  4. Strukmyer LLC dba Strukmyer Medical

    Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

    High risk
  5. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  6. Imperial Palace Commodity -Dongguan- Co., Ltd.

    FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

    High risk
  7. Center for Instrumental Analysis of China Pharmaceutical University

    Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.

    High risk
  8. Global Calcium Pvt. Limited

    FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.

    High risk
  9. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  10. Kardesler Ucan Yaglar Sanayi Anonim Sirketi

    Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

    High risk
  11. Sanofi

    FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.

    High risk
  12. Atlanta Supersource, Inc.

    Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.

    High risk
  13. INCELL Corporation LLC

    FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.

    High risk
  14. Indoco Remedies Limited

    FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.

    High risk
  15. Bhargava Phytolab Private Limited

    FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.

    High risk
  16. Viatris, Inc.

    FDA warns Viatris that its Indore, India, drug plant had unreliable quality data and weak investigations.

    High risk
  17. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  18. Akron Formulations India Private Limited

    Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.

    High risk
  19. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  20. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  21. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  22. Guangzhou Four E’s Scientific Co., Ltd.

    FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.

    High risk
  23. LCC Ltd.

    FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

    High risk
  24. Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.

    FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.

    High risk
  25. Catwalk Cosmetic Laboratories Pty Ltd.

    FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.

    High risk
  26. Eurosirel S.P.A

    FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.

    High risk
  27. Hangzhou Huiji Biotechnology Co., Ltd.

    FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.

    High risk
  28. Originitalia SRL

    FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.

    High risk
  29. Unexo Lifesciences, Private Limited

    FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.

    High risk
  30. Colgate-Palmolive/Tom's of Maine, Inc.

    FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.

    High risk
  31. Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.

    FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.

    High risk
  32. Zhejiang Qimei Cosmetics Co., Ltd.

    Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.

    High risk
  33. Multaler et Cie SAS

    FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.

    High risk
  34. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  35. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  36. Choice All Natural, Inc. dba Om Botanical

    FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.

    High risk
  37. Diora Kimya Sanayi ve Ticaret Limited Sirketi

    FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.

    High risk
  38. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  39. Omni Lens Pvt. Ltd.

    FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.

    High risk
  40. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  41. MMC Healthcare Ltd.

    FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.

    High risk
  42. Supercore Products Group, Inc.

    FDA warns Supercore that Hard Steel and Gold Hard Steel Plus are unapproved, mislabeled drugs with hidden sildenafil; Hard Steel also has acetaminophen.

    High risk
  43. Makra Kozmetika D.O.O.

    FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.

    High risk
  44. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  45. Diamond Chemical Co., Inc.

    Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.

    High risk
  46. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  47. Azurity Pharmaceuticals, Inc.

    FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.

    High risk
  48. Accupack Midwest, Inc.

    Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.

    High risk
  49. Wittman Pharma, Inc.

    FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.

    High risk
  50. Aerosol and Liquid Packaging, Inc.

    FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.

    High risk